Literature DB >> 22409585

Patterns of care in the management of seminoma stage I: results from a European survey.

Carla Y Vossen1, Alan Horwich, Gedske Daugaard, Hein van Poppel, Susanne Osanto.   

Abstract

UNLABELLED: Study Type - Therapy (practise pattern survey). Level of Evidence 3b. What's known on the subject? and What does the study add? The uncertainties about differences in relapse and rates of other late events such as second malignancy and cardiovascular events for the three post-orchidectomy strategies in seminoma stage I patients has led to debates about whether the three strategies are equally effective and safe. The differences in interpretation of the data as well as the debates are likely to result in differences in treatment after orchidectomy in seminoma stage I patient management. Current care patterns after orchidectomy are, however, unknown. We assessed patterns of care for seminoma stage I patients after orchidectomy by distributing a survey among doctors treating such patients across Europe. The 969 respondents showed large differences in care strategies between specialties and countries that indicate the need for research into long-term relapse rates and long-term adverse effects to standardize and optimize care for seminoma stage I patients.
OBJECTIVE: • To assess precise patterns of care after orchidectomy in Europe for stage I seminoma patients, we aimed to perform a survey among doctors in the various European countries. PATIENTS AND METHODS: • We distributed a survey in 2009 and 2010 among American Society of Clinical Oncology and European Association of Urology members.
RESULTS: • In total, 969 questionnaires were included in the analysis. More than half of the 969 physicians (58%) currently offer only one post-surgical treatment: 18% only surveillance, 19% only radiotherapy and 21% only chemotherapy. Thirteen percent of the 969 physicians currently offer all three strategies, 25% offer surveillance and adjuvant radiotherapy or chemotherapy, and 5% offer either adjuvant radiotherapy or chemotherapy without surveillance. • We found large differences in care patterns between specialties and countries. Even within countries, care after orchidectomy was not standardized. • Before 2005, 73% of the physicians offered only one treatment and of those 51% gave adjuvant radiotherapy.
CONCLUSIONS: • Large differences in pattern of care after orchidectomy for stage I seminoma patients exist between specialties and countries within Europe. • More information on long-term relapse rates and long-term adverse effects of the three strategies is needed to standardize and optimize care after orchidectomy.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2012        PMID: 22409585     DOI: 10.1111/j.1464-410X.2011.10887.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Testicular cancer: Underestimating radiotherapy toxicity for stage I seminoma.

Authors:  Nicklas Pfanzelter; Justin E Bekelman
Journal:  Nat Rev Urol       Date:  2012-04-17       Impact factor: 14.432

Review 2.  Contemporary management of stage I and II seminoma.

Authors:  Peter Chung; Padraig Warde
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

3.  Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.

Authors:  Peter Chung; Gedske Daugaard; Scott Tyldesley; Eshetu G Atenafu; Tony Panzarella; Christian Kollmannsberger; Padraig Warde
Journal:  Cancer Med       Date:  2014-09-19       Impact factor: 4.452

4.  Increased pancreatic cancer risk following radiotherapy for testicular cancer.

Authors:  Michael Hauptmann; Tom Børge Johannesen; Ethel S Gilbert; Marilyn Stovall; Flora E van Leeuwen; Preetha Rajaraman; Susan A Smith; Rita E Weathers; Berthe M P Aleman; Michael Andersson; Rochelle E Curtis; Graça M Dores; Joseph F Fraumeni; Per Hall; Eric J Holowaty; Heikki Joensuu; Magnus Kaijser; Ruth A Kleinerman; Frøydis Langmark; Charles F Lynch; Eero Pukkala; Hans H Storm; Leila Vaalavirta; Alexandra W van den Belt-Dusebout; Lindsay M Morton; Sophie D Fossa; Lois B Travis
Journal:  Br J Cancer       Date:  2016-09-06       Impact factor: 7.640

5.  Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma.

Authors:  A Horwich; S D Fossa; R Huddart; D P Dearnaley; S Stenning; M Aresu; J M Bliss; E Hall
Journal:  Br J Cancer       Date:  2013-11-21       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.